Chronic lymphocytic leukaemia (CLL) is a slow-growing cancer affecting white blood cells, primarily diagnosed in people over 50. While current medicine cannot cure CLL, modern therapies can control the disease and help many people live for years with good quality of life.

Understanding the Approach to Managing CLL

When someone receives a diagnosis of chronic lymphocytic leukaemia, the path forward isn’t always immediate treatment. This might seem puzzling at first—why wait if cancer is present? The answer lies in understanding how CLL behaves. Unlike many other cancers, CLL often develops very slowly, sometimes over many years. Research has shown that starting treatment before certain warning signs appear doesn’t help people live longer, and since all treatments carry potential side effects, doctors often recommend a careful monitoring approach first.^[12]

The main goals when treating CLL focus on controlling the disease rather than attempting to eliminate every cancer cell. This means managing symptoms when they arise, slowing down disease progression, and maintaining the best possible quality of life. Each person’s treatment plan looks different, shaped by factors such as the stage of their cancer, their age, overall health condition, and the specific characteristics of their cancer cells at the molecular level.^[2][10]

Medical societies have established standard treatments that doctors follow, based on years of clinical experience and research. At the same time, scientists continue investigating new therapies through clinical trials. These research studies test promising drugs and treatment approaches that might one day become standard care. Some people with CLL may have the opportunity to participate in these trials, potentially accessing innovative treatments while contributing to medical knowledge that will help future patients.

Standard Treatment Approaches

Active Surveillance: The Watch and Wait Strategy

For many people newly diagnosed with CLL, the first treatment recommendation is actually no treatment at all, at least not right away. This approach is called active surveillance or “watchful waiting.” During this period, your healthcare team doesn’t simply ignore the cancer—instead, they monitor it carefully through regular check-ups, blood tests, and physical examinations. The frequency of these visits depends on your specific situation, but they’re designed to catch any signs that the cancer is becoming more active.^[12][15]

Active surveillance works because CLL typically progresses slowly. Many people live for years without needing active treatment. During this time, your medical team watches for specific indicators that suggest it’s time to begin therapy. These might include worsening blood counts, enlarging lymph nodes, increasing fatigue, or frequent infections. The surveillance period also gives you time to maintain your normal activities and avoid treatment side effects until they become necessary.^[7]

While under surveillance, you’re encouraged to focus on staying as healthy as possible. This means maintaining good nutrition, staying physically active within your abilities, keeping up with recommended vaccinations to prevent infections, and attending all scheduled appointments. Your healthcare team will provide guidance on recognizing symptoms that should prompt an immediate call, such as high fever, unexplained bleeding, or sudden weakness.

When Treatment Begins

Active treatment for CLL usually starts when the disease shows signs of progression or when symptoms begin affecting your daily life. The decision to start treatment is based on several factors: blood test results showing worsening counts, physical examination findings like significantly enlarged lymph nodes or spleen, symptoms such as severe fatigue or weight loss, or frequent infections indicating your immune system is struggling.^[12]

Targeted Therapy: Modern Medicine’s Precision Approach

Targeted therapy represents a major advancement in treating CLL. Unlike older treatments that affect all rapidly dividing cells, targeted medicines are designed to attack specific features of cancer cells while leaving normal cells relatively unharmed. These drugs work by blocking particular proteins or pathways that cancer cells need to survive and multiply.^[12]

Several targeted drugs have become standard treatment for CLL. These medicines can be used alone or combined with other treatments depending on your situation. Some targeted therapies work by blocking signals that tell cancer cells to grow, while others help your immune system recognize and attack the abnormal cells. Your doctor chooses specific targeted drugs based on genetic tests performed on your cancer cells, which reveal which treatments are most likely to work for you.^[10]

The advantage of targeted therapy is that many people tolerate it better than traditional chemotherapy. Side effects still occur but are often less severe. Common issues include fatigue, digestive problems like diarrhea or nausea, temporary increases in infection risk, and occasionally skin rashes. Your healthcare team monitors you closely during treatment to manage these effects and adjust your medication if needed.^[12]

Chemoimmunotherapy: Combining Two Treatment Types

Chemoimmunotherapy combines traditional chemotherapy drugs with immunotherapy medicines. Chemotherapy works by killing rapidly dividing cells, including cancer cells. Immunotherapy medicines, often antibodies created in laboratories, help your immune system fight the cancer more effectively. When used together, these treatments can be more powerful than either approach alone.^[12][15]

This combination therapy is typically given in cycles, with treatment periods followed by rest periods to allow your body to recover. The specific drugs, dosages, and cycle length vary based on your health status and how you respond to treatment. Most people receive chemoimmunotherapy through an intravenous line in an outpatient clinic, though some medications can be taken as pills at home.

Side effects from chemoimmunotherapy can be more noticeable than from targeted therapy alone. Common effects include reduced blood cell counts leading to anemia, fatigue, increased infection risk, easy bruising or bleeding, hair thinning or loss, mouth sores, and digestive upset. Your healthcare team provides medications to prevent or manage these side effects and teaches you warning signs that require immediate medical attention, such as fever, severe weakness, or unusual bleeding.^[15]

The duration of treatment varies considerably between individuals. Some people complete treatment within several months, while others may need therapy for a year or longer. Regular monitoring through blood tests and examinations helps your doctor determine when treatment can stop and assess how well the cancer is responding.

Supportive Treatments and Additional Care

Beyond therapies targeting the cancer itself, people with CLL often need supportive treatments. Because CLL weakens the immune system, preventing infections becomes crucial. Your doctor may prescribe antibiotics to take at the first sign of infection or even preventively if you’re particularly vulnerable. Vaccinations against influenza, pneumonia, and other infectious diseases are strongly recommended, though your doctor will time these carefully around your treatment schedule for maximum effectiveness.^[15]

If your blood counts drop significantly, you might need blood transfusions to replace red blood cells and treat anemia, or platelet transfusions if your platelets become dangerously low and you’re at risk for bleeding. Steroid medications may be prescribed to help control specific complications of CLL, such as autoimmune problems where your body mistakenly attacks its own blood cells.

In rare situations, other treatments become necessary. Radiotherapy, which uses high-energy radiation to kill cancer cells, might be directed at enlarged lymph nodes causing pain or other problems. Very rarely, surgery to remove the spleen may be recommended if this organ becomes severely enlarged and causes discomfort or worsens blood cell counts.^[15]

Treatment in Clinical Trials: Exploring New Possibilities

Clinical trials represent the cutting edge of CLL treatment research. These carefully designed studies test new drugs, new combinations of existing drugs, or entirely new treatment approaches. Participating in a clinical trial may give you access to therapies that aren’t yet available outside of research settings, while also helping advance medical knowledge that will benefit future patients.

Understanding Clinical Trial Phases

Clinical trials progress through distinct phases, each with specific goals. Phase I trials focus primarily on safety—researchers want to determine what dose of a new drug can be given safely and what side effects occur. These trials typically involve small numbers of patients and test gradually increasing doses to find the right balance between effectiveness and tolerability.^[7]

Phase II trials expand the investigation to more patients and focus on whether the treatment actually works against the cancer. Researchers measure how many patients respond to treatment, how long responses last, and continue monitoring for side effects. If a treatment shows promise in Phase II, it moves forward to Phase III.

Phase III trials compare the new treatment against current standard treatments. These large studies involving hundreds or thousands of patients provide the evidence needed to determine whether a new therapy truly represents an improvement. Some patients in these trials receive the new treatment, while others receive standard care, allowing researchers to directly compare outcomes.^[7]

Innovative Molecules and Therapies Being Studied

Researchers are investigating several promising approaches for treating CLL. One exciting area involves drugs that target specific pathways cancer cells use for survival and growth. These novel targeted therapies work by blocking proteins that send growth signals inside cancer cells or by preventing cancer cells from evading normal cell death processes. Some of these experimental drugs have shown encouraging results in early trials, with patients experiencing shrinkage of enlarged lymph nodes and improvement in blood counts.^[14]

Another innovative approach being tested is CAR T-cell therapy. This complex treatment involves collecting some of your own immune cells, genetically modifying them in a laboratory to recognize and attack CLL cells, then infusing them back into your body. The modified cells can multiply inside your body and potentially provide long-lasting cancer control. CAR T-cell therapy is still being studied in clinical trials for CLL, and while it has shown impressive results in other blood cancers, researchers are working to optimize it specifically for CLL patients.^[2][10][12]

Bispecific T-cell engagers, or BiTEs, represent another immunotherapy approach under investigation. These specially designed molecules act like bridges, physically connecting cancer cells to your immune system’s T cells. Once connected, the T cells can directly attack and destroy the cancer cells. This therapy is administered through infusions and is being tested in patients whose CLL has returned after other treatments or hasn’t responded well to standard therapies.^[12]

Where Trials Are Happening and Who Can Participate

Clinical trials for CLL are conducted at medical centers around the world, including in the United States, Europe, and many other regions. Major cancer centers and academic hospitals often host multiple trials. Some trials are also available at community hospitals that partner with research networks. The location of trials can vary depending on the specific study and the institutions involved.^[7]

Eligibility for clinical trials depends on many factors. Researchers carefully define who can participate to ensure patient safety and obtain meaningful results. Common considerations include your CLL stage, whether you’ve received previous treatment and how you responded, your age and general health condition, other medical conditions you might have, and specific genetic or molecular features of your cancer cells. Your healthcare provider can search clinical trial databases to find studies that match your situation.

Preliminary Results from Recent Research

Early results from some clinical trials have been encouraging. Studies testing new targeted therapy drugs have reported that many patients experience significant reduction in their cancer burden, with some achieving complete disappearance of detectable cancer cells from their blood and bone marrow. Improvements in blood counts, reduction in enlarged lymph nodes, and relief of symptoms like fatigue have also been documented. Safety profiles from these trials suggest that many new agents are reasonably well-tolerated, though each drug has its own specific side effect pattern that researchers continue to study.^[14]

Research into combination approaches—using multiple targeted drugs together or combining targeted drugs with immunotherapy—has also shown promise. Some studies suggest that these combinations might work better than single drugs alone, potentially leading to longer periods without disease progression. However, all these findings remain preliminary until larger, longer studies confirm the benefits.

When Cancer Returns: Managing Relapsed or Refractory CLL

CLL is characterized by periods of remission (when the disease is controlled and symptoms are minimal or absent) followed by relapse, when the cancer becomes active again. A relapse might happen slowly, with gradually worsening blood counts or enlarging lymph nodes, or more quickly with return of symptoms. The term refractory CLL refers to cancer that doesn’t respond well to treatment or stops responding after initially improving.^[12][15]

When CLL relapses, you don’t necessarily need immediate treatment. Just as with newly diagnosed disease, doctors may recommend careful monitoring if the relapse is progressing slowly and you’re not experiencing troublesome symptoms. When treatment becomes necessary, your doctor will likely recommend additional testing to understand why the cancer returned and which treatments might work best this time.

Treatment options for relapsed CLL include many of the same approaches used initially—targeted therapies, chemoimmunotherapy, or combinations of different drugs. However, doctors often choose different medications than you received before, especially if the cancer stopped responding to your previous treatment. Your healthcare team considers how long your remission lasted, which drugs you’ve already tried, how well you tolerated previous treatments, and any new genetic changes in your cancer cells that might affect treatment choices.^[12]

For people whose CLL has relapsed multiple times or proven difficult to control, more intensive options may be considered. Stem cell transplant, also called bone marrow transplant, involves high doses of chemotherapy followed by infusion of healthy blood-forming stem cells. This intensive procedure carries significant risks but may offer hope for long-term disease control when other treatments haven’t worked. Because of the risks involved, stem cell transplant is typically reserved for younger, healthier patients whose disease cannot be controlled with other methods.^[2][12]

Many people with CLL go through several treatment cycles over the course of years, experiencing multiple remissions and relapses. This pattern can be emotionally challenging, but each remission offers time to live well and enjoy life. Modern treatments have extended survival significantly, and many people live for many years with CLL, even with relapses.

Most common treatment methods

• Active surveillance (watchful waiting)
  • Careful monitoring through regular check-ups, blood tests, and physical examinations without immediate active treatment
  • Recommended for people with early-stage CLL who have no symptoms or minimal disease
  • Frequency of monitoring depends on individual situation and disease characteristics
  • Allows patients to maintain normal life without treatment side effects until therapy becomes necessary
• Targeted therapy
  • Medicines designed to attack specific features or proteins on cancer cells
  • Works by blocking signals that tell cancer cells to grow and survive
  • Can be used alone or combined with other treatments
  • Generally better tolerated than traditional chemotherapy with fewer side effects
  • Choice of specific drugs based on genetic tests of cancer cells
• Chemoimmunotherapy
  • Combination of traditional chemotherapy drugs with immunotherapy medicines
  • Chemotherapy kills rapidly dividing cancer cells
  • Immunotherapy (laboratory-made antibodies) helps immune system fight cancer
  • Usually given in cycles with treatment periods followed by rest periods
  • Most commonly administered through intravenous infusion in outpatient settings
• Supportive care
  • Antibiotics to prevent or treat infections
  • Vaccinations against flu, pneumonia, and other infectious diseases
  • Blood transfusions to replace red blood cells when anemia is severe
  • Platelet transfusions when platelets are dangerously low
  • Steroid medications to control specific complications
• Radiotherapy
  • Uses high-energy radiation to kill cancer cells
  • May be directed at enlarged lymph nodes causing pain or problems
  • Used in specific situations when other treatments aren’t suitable
  • Can be used to treat areas where cancer is causing symptoms
• CAR T-cell therapy (in clinical trials)
  • Involves collecting patient’s own immune cells and genetically modifying them
  • Modified cells are designed to recognize and attack CLL cells
  • Cells are infused back into patient where they multiply and fight cancer
  • Currently being studied in clinical trials for CLL patients
  • May provide long-lasting cancer control in some patients
• Bispecific T-cell engagers (BiTEs) (in clinical trials)
  • Specially designed molecules that connect cancer cells to immune system T cells
  • Acts as a bridge allowing T cells to directly attack cancer cells
  • Administered through intravenous infusions
  • Being tested in patients with relapsed or refractory CLL
• Stem cell transplant
  • Involves high doses of chemotherapy followed by infusion of healthy blood-forming stem cells
  • Can sometimes be used for patients whose disease is difficult to control
  • Carries significant risks and requires careful patient selection
  • Typically reserved for younger, healthier patients when other treatments haven’t worked